Infant PCV Study
Participants needed: Infants 2 months of age who have not yet received their routine vaccines
A study to look at the safety and effectiveness of a new pneumococcal vaccine in healthy infants.If you are interested, please contact Aimee.GonzalezdeArmas@iwk.nshealth.ca.
Pneumococcal vaccine is routinely given to infants in Canada to protect them against pneumococcal disease which can result in serious infections. Pneumococcal disease is caused by the bacteria Streptococcus pneumoniae, or “pneumococcus”. These bacteria can cause infection of the middle ear (otitis), of the lungs (pneumonia), or become more serious. In Nova Scotia and most other provinces/territories in Canada, a vaccine called Prevnar-13™, which protects against 13 types of pneumococcal infection, is given as 3 injections at 2, 4, and 12 months of age. There is a new vaccine that protects against 8 additional types. In this study, we are looking to compare the safety and effectiveness of the new vaccine that protects against 21 types with the routine vaccine called Prevnar-13™.
Your child can take part in this study if:
- He/she is healthy
- He/she is 2 months of age
- He/she has not yet received their routine vaccines
- You are able to understand the study and procedures, the risks and benefits involved, and agree for your child to take part by signing the consent form
What Will I Have to Do?
Your child will have a total of 6 visits to the IWK and you will be asked to complete 5 phone calls over a 16-19month period. The visits and phone calls will take around 4-5hours over the entire study period.
Contact Aimee Gonzalez de Armas